[Federal Register Volume 88, Number 222 (Monday, November 20, 2023)]
[Notices]
[Page 80729]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-25572]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Advisory Committee on Blood and Tissue Safety and 
Availability

AGENCY: Office of the Assistant Secretary for Health, Office of the 
Secretary, Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The U.S. Department of Health and Human Services is hereby 
giving notice that the Advisory Committee on Blood and Tissue Safety 
and Availability (ACBTSA) will hold a virtual meeting. The meeting will 
be open to the public via webcast. The committee will discuss and vote 
on recommendations related to surge capacity for blood and blood 
products.

DATES: The meeting will take place virtually on January 11, 2024 from 
approximately 9:00 a.m.--5:00 p.m. Eastern Time (ET). Meeting times are 
tentative and subject to change. The confirmed times and agenda items 
for the meeting will be posted on the ACBTSA web page at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2024-01-11/index.html when this information becomes available.

FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal 
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS 
Policy, Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Tower Building, 1101 Wootton Parkway, 
Rockville, MD, 20852. Email: [email protected]. Phone: 202-795-7608.

SUPPLEMENTARY INFORMATION: On the day of the meeting, please go to 
https://www.hhs.gov/live/index.html to view the meeting. The public 
will have an opportunity to present their views to the ACBTSA by 
submitting a written public comment. Comments should be pertinent to 
the meeting discussion. Persons who wish to provide written public 
comment should review instructions at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2024-01-11/index.html and respond by midnight January 3, 2024, ET. Written 
public comments will be accessible to the public on the ACBTSA web page 
prior to the meeting.
    Background and Authority: The ACBTSA is a discretionary Federal 
advisory committee and is governed by the provisions of the Federal 
Advisory Committee Act (FACA), Public Law 92-463, as amended (5 U.S.C. 
app), which sets forth standards for the formation and use of advisory 
committees. The ACBTSA functions to provide advice to the Secretary 
through the Assistant Secretary for Health on a range of policy issues 
to include: (1) Identification of public health issues through 
surveillance of blood and tissue safety issues with national survey and 
data tools; (2) identification of public health issues that affect 
availability of blood, blood products, and tissues; (3) broad public 
health, ethical, and legal issues related to the safety of blood, blood 
products, and tissues; (4) the impact of various economic factors 
(e.g., product cost and supply) on safety and availability of blood, 
blood products, and tissues; (5) risk communications related to blood 
transfusion and tissue transplantation; and (6) identification of 
infectious disease transmission issues for blood, organs, blood stem 
cells and tissues. The Committee has met regularly since its 
establishment in 1997.

    Dated: November 2, 2023.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue 
Safety and Availability, Office of Infectious Disease and HIV/AIDS 
Policy.
[FR Doc. 2023-25572 Filed 11-17-23; 8:45 am]
BILLING CODE 4150-28-P